

DAFTAR RUJUKAN

1. John S. Complication in diabetic nephropathy. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2016;10:247-9.
2. Ahmad J. Management of diabetic nephropathy: Recent progress and future perspective. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2015;9:343-58.
3. Pyrama R, Kansara A, Banerjia MA, Loney-Hutchinson L. Chronic kidney disease and diabetes. *Maturitas*. 2012;71:94-103.
4. WHO. *Global Report on Diabetes*: World Health Organization; 2016.
5. Jaacks LM, Siegel KR, Gujral UP, Narayan KMV, Hubert R, Hubert OC. Type 2 diabetes: A 21st century epidemic. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2016;30:331-43.
6. NCD-RisC. Worldwide trends in diabetes since 1980 : a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet*. 2016;387:1513-30.
7. Boer IHd, Rue TC, Hall YN, Heagerty aJ, Weiss NS, Himmelfarb J. Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States. *JAMA*. 2011;305:2532-9.
8. Li L, Jick S, Breitenstein S, Michel A. Prevalence of Diabetes and Diabetic Nephropathy in a Large U.S. Commercially Insured Pediatric Population, 2002–2013. *Diabetes Care*. 2016;39:78-184.
9. Al-Rubeaan K, Youssef AM, Subhani SN, Ahmad NA, Al-Sharqawi AH, Al-Mutlaq HM, et al. Diabetic Nephropathy and Its Risk Factors in a Society with a Type 2 Diabetes Epidemic: A Saudi National Diabetes Registry-Based Study. *PLOS ONE*. 2014;9(2):e88956.
10. Goñi MJ, Mozas D, Forga L, Anda E, Ibañez B, Cambra K. Incidence and Risk Factors Involved in the Development of Nephropathy in Patients with Type 1 Diabetes Mellitus: Follow Up Since Onset. *Can J Diabetes*. 2016;40:258-63.
11. Abougambou SSI, Abougambou AS, Barghash SS. A Study Evaluating the Prevalence of Nephropathy among Type 2 Diabetes Patients Attending a Teaching Hospital in Malaysia. *J Clin Nephrol Ren Care*. 2016;2(1).
12. Loh PT, Toh MPHS, Molina JA, Vathsala A. Ethnic disparity in prevalence of diabetic kidney disease in an Asian primary healthcare cluster. *Nephrology*. 2015;20:216-23.
13. Soegondo S, Prodjosudjadi W, Setiawati A. Prevalence and risk factors for microalbuminuria in a cross-sectional study of type-2 diabetic patients in Indonesia : a subset of DEMAND study. *Med J Indones*. 2009;18:124-30.
14. Salinero-Fort MÁ, Andrés-Rebollo FJS, Burgos-Lunar Cd, Abánades-Herranz JC, Carrillo-de-Santa-Pau E, Chico-Moraleja RM, et al. Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study: Association with chronic kidney disease. *Journal of Diabetes and Its Complications*. 2016;30(227-236).

15. Thomas S, Karalliedde J. Other Complication of Diabetes: Diabetic Nephropathy. *Medicine*. 2014;43(1):P 20–5.
16. Ang YG, Heng BH, Saxena N, Liew STA, Chong P-N. Annual all-cause mortality rate for patient with diabetic kidney disease in Singapore. *Journal of Clinical & Translational Endocrinology*. 2016;4:1-6.
17. Lim AK. Diabetic nephropathy – complications and treatment. *International Journal of Nephrology and Renovascular Disease*. 2014;7:2014.
18. Ismaili FA, Salmi IA, Maimani YA, Metry AM, Marhoobi HA, Hola A, et al. Epidemiological Transition of End-Stage Kidney Disease in Oman. *Kidney International Reports*. 2017;2:27-35.
19. PERNEFRI. 9th Report Of Indonesian Renal Registry. 2016.
20. Ariyanto. Beberapa faktor risiko penyakit ginjal kronik (PGK) stadium V pada kelompok usia di bawah 50 tahun. Universitas Diponegoro Thesis unpublished. 2016.
21. Atkins RC, Zimmet P. Diabetic kidney disease: act now or pay later. *JNEPHROL*. 2010;23(01):1-4.
22. Muthuppalaniappan VM, Sheaff M, Yaqoob MM. Systemic Disease And The Kidney : Diabetic nephropathy. *MEDICINE*. 2015;43(9):520-5.
23. Zheng W, Chen L. Factor analysis of diabetic nephropathy in Chinese patients. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2011;5:130-6.
24. Bjornstad P, Snell-Bergeon JK, Rewer M, Jalal D, Chonchol MB, Johnson RJ, et al. Early Diabetic Nephropathy : A Complication of Reduced insulin sensitivity in type 1 diabetes. *Diabetes Care*. 2013;36:3678-83.
25. Gupta RK, Gupta R, Maheshwari VD, Mawliya M. Impact of smoking on microalbuminuria and urinary albumin creatinine ratio in non-diabetic normotensive smokers. *Indian Journal of Nephrology*. 2014;24(2):92-6.
26. Lim S, Chellumuthi C, Crook N, Rush E, Simmons D. Low prevalence of retinopathy, but high prevalence of nephropathy among Maori with newly diagnosed diabetes—Te Wai o Rona: Diabetes Prevention Strategy. *Diabetes Research and Clinical Practice*. 2008;80:271-4.
27. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main Risk Factors for Nephropathy in Type 2 Diabetes Mellitus Are Plasma Cholesterol Levels, Mean Blood Pressure, and Hyperglycemia. *Arch Intern Med*. 1998;158:998-1004.
28. Morton J, Zoungas S, Li Q, Patel AA, Chalmers J, Woodward M, et al. Low HDL Cholesterol and the Risk of Diabetic Nephropathy and Retinopathy Results of the ADVANCE study. *Diabetes Care*. 2012;35:2201-6.
29. Almutairi MA, Said SM, Zainuddin H. Predictors of Poor Glycemic Control Among Type Two Diabetic Patients. *American Journal of Medicine and Medical Sciences*. 2013;3:17-21.
30. Purwitaningtyas RY, Putra IWGAE, Wirawan DN. Faktor Risiko Kendali Glikemik Buruk pada Penderita Diabetes Melitus Tipe 2 di Puskesmas Kembangitan Kabupaten Banyuwangi. *Public Health and Preventive Medicine Archive*. 2015;3.

31. Nakajima H, Kaneita Y, Yokoyama E, Harano S, Tamaki T, Ibuka E, et al. Association between sleep duration and hemoglobin A1c level. *Sleep Medicine, Elsevier*. 2008;9:745-52.
32. Chaput J-P, Després J-P, Bouchard C, Astrup A, Tremblay A. Sleep duration as a risk factor for the development of type 2 diabetes or impaired glucose tolerance: Analyses of the Quebec Family Study. *Sleep Medicine, Elsevier*. 2009;10:919-24.
33. Lin C-L, Tsai Y-H, Yeh MC. Associations between sleep duration and type 2 diabetes in Taiwanese adults: A population-based study. *Journal of the Formosan Medical Association*. 2016;xx:1-7.
34. Lou P, Zhang P, Zhang L, Chen P, Chang G, Zhang N, et al. Effects of sleep duration and sleep quality on prevalence of type 2 diabetes mellitus: A 5-year follow-up study in China. *Diabetes Research and Clinical Practice*. 2015;109:178-84.
35. Kachi Y, Ohwaki K, Yano E. Association of sleep duration with untreated diabetes in Japanese men. *Sleep Medicine*. 2012;13:307-9.
36. Cauter EV, Spiegel K, Tasali E, Leproult R. Metabolic consequences of sleep and sleep loss. *Sleep Medicine, Elsevier*. 2008;9:S23-S8.
37. Bianchi C, Penno G, Daniele G, Russo E, Giovannitti MG, Prato SD, et al. The metabolic syndrome is related to albuminuria in Type 2 diabetes. *Diabetic Medicine*. 2008;25:1412-8.
38. Meng L-L, Liu Y, Geng R-N, Tang Y-Z, Li D-Q. Association of diabetic vascular complications with poor sleep complaints. *Diabetology & Metabolic Syndrom*. 2016;8.
39. Park H, Kim K. Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean women. *BMC Women's Health*. 2013;13.
40. The PC, Kolibu FK, Rattu AJM. Hubungan Antara Penggunaan Pil Keluarga Berencana dengan Hipertensi pada Pasangan Usia Subur di Desa Sangaji Nyeku Kecamatan Tabaru Kabupaten Halmahera Barat. *PHARMACONJurnal Ilmiah Farmasi – UNSRAT*. 2017;6.
41. Pusdatin-Kemendes. Situasi dan Analisis Keluarga Berencana. *INFODATIN*. 2014.
42. Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, Diez-Espino J, Mundet-Tuduri X, Puente JB-DI, et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. *BMC Nephrology*. 2013;4.
43. Endarti AT, Handito A. The Relationship Between Non-communicable Diseases History and Health-Related Quality of Life. *KEMAS*. 2016;12(1):120-30.
44. Kent S, Schlackow I, Lozano-Kühne J, Reith C, Emberson J, Haynes R, et al. What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? *BMC Nephrology*. 2015;16(65).
45. Lewis G, P.Maxwell A. Risk factor control is key in diabetic nephropathy. *The Practitioner*. 2014;258(1768):13-7.

46. Powers AC. Diabetes Mellitus. Chapter 18. in Harrison's Endocrinology. 2nd ed. Jameson JL, editor: The McGraw-Hill Companies, Inc; 2010.
47. Chang Y-H, Chang D-M, Lin K-C, Hsieh C-H, Lee Y-J. High-density lipoprotein cholesterol and the risk of nephropathy in type 2 diabetic patients. *Nutrition, Metabolism & Cardiovascular Diseases*. 2013;23:751-7.
48. Abdulkhameem Hamood Alrawahi, Syed Gauhar A. Rizvi, Dawood Al-Riami, Al-Anqoodi Z. Prevalence and Risk Factors of Diabetic Nephropathy in Omani Type 2 Diabetics in Al-Dakhiliyah Region. *Oman Medical Journal*. 2012;27.
49. Hoque S., Muttalib MA., Islam MI., PA. K, Akter N, T. A. Prevalence of Nephropathy with Evaluation of HbA1c Level and other Associated Risk Factors in Type 2 Diabetic Patients in a Tertiary Level Hospital. *KYAMC Journal*. 2017;8(1).
50. MacIsaac RJ, Jerums G, Watts GF. Diabetic Chronic Kidney Disease. Sec. 2. in *Diabetes Chronic Complications*. Third Edition ed: A John Wiley & Sons, Ltd.; 2012.
51. Gul CB, Gul OO, Cander S, Eroglu A, Hartavi M, Keni N, et al. Relationship between glycemic control, microalbuminuria and cognitive functions in elderly type 2 diabetic patients. *Renal Failure*. 2014;36:1258-62.
52. Yulianti E. Mikroalbuminuria pada Penderita Diabetes Mellitus Tipe 2 Hipertensif. *Jurnal Penelitian Saintek*. 2009;14:77-96.
53. Nelson RG, Pavkov ME, Hanson RL, Knowler WC. Changing course of diabetic nephropathy in the Pima Indians. *Diabetes Research and Clinical Practice*. 2008;82s:s10-s4.
54. Vinod PB. Pathophysiology of diabetic nephropathy. *Clinical Queries: Nephrology*. 2012;0102:121-6.
55. Vujičić B, Turk T, Crnčević-Orlić Ž, Đorđević G, Rački S. Diabetic Nephropathy. Sec. 4. in *Pathophysiology and Complications of Diabetes Mellitus*. In Tech. 2012.
56. Zhang C, Li S, Zhang X, Liu H, Luo Y. Association of ApoE gene with type 2 diabetic nephropathy in a Chinese population: A meta-analysis of case-control studies. *Annales d'Endocrinologie*. 2015;76:601-13.
57. Alejandra Guillermina Miranda-Díaz, Leonardo Pazarín-Villaseñor, Francisco Gerardo Yanowsky-Escatell, Andrade-Sierra J. Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease. *Journal of Diabetes Research*. 2016.
58. Aghadavod E, Khodadadi S, Baradaran A, Nasri P, Bahmani M, Rafieian-Kopaei M. Role of Oxidative Stress and Inflammatory Factors in Diabetic Kidney Disease. *Iranian Journal of Kidney Diseases*. 2016;10:337-43.
59. Bhattacharjee N, Barma S, Konwar N, Dewanjee S, Manna P. Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update. *European Journal of Pharmacology*. 2016;791:8-14.
60. Satirapoj B, Adler SG. Comprehensive approach to diabetic nephropathy. *Kidney Research and Clinical Practice*. 2014;33 (2014) 121–131:121-31.
61. Lingaraj U, Annamalai C, Radhakrishnan H. Diabetes and kidney disease. *Apollo Medicine*. 2013;10(118-125).

62. ADA. Microvascular complications and foot care. Sec. 10. In Standards of Medical Care in Diabetes-2017. *Diabetes Care*. 2017;40(Suppl.1):S88-S98.
63. Jeng C-J, Hsieh Y-T, Yang C-M, Yang C-H, Lin C-L, Wang I-J. Diabetic Retinopathy in Patients with Diabetic Nephropathy: Development and Progression. *PLOS ONE*. 2016;11(8).
64. Hsieh M-C, Hsieh§ Y-T, Cho T-J, Chen J-F, Lin S-D, Chen H-C, et al. Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control. *European Journal of Clinical Investigation*. 2011;41:870–8.
65. PERKENI. Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2011. Jakarta: PERKENI; 2011.
66. NKF-KDOQI. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. *Am J Kidney Dis*. 2012;60(5):850-86.
67. Jose MJ, Varkey V, Chandni R, Zubaida P, Maliekkal J. The Role of Smoking as a Modifiable Risk Factor in Diabetic Nephropathy. *Journal of The Association of Physicians of India*. 2016;64.
68. Parving H-H, Lewis J, Ravid M, Remuzzi G, Hunsicker L. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. *Kidney International*. 2006;69:2057-63.
69. Lova S, Lim SC, Zhang X, Zhou S, Yeoh LY, Liu YL, et al. Development and validation of a predictive model for Chronic Kidney Disease progression in Type 2 Diabetes Mellitus based on a 13-year study in Singapore. *Diabetes Research and Clinical Practice*. 2017;123:49-54.
70. Ritz E, Viberti GC, Ruilope LM, Rabelink AJ, Jr JLI, Katayama S, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. *Diabetologia*. 2010;53:49-57.
71. Costa DdAF, Todiras M, Campos LA, Cipolla-Neto J, Bader M, Baltatu OC. Sex-dependent differences in renal angiotensinogen as an early marker of diabetic nephropathy. *Acta Physiol*. 2015;213:740-6.
72. Changa W-T, Huang M-C, Chung H-F, Chiu Y-F, Chen P-S, Chen F-P, et al. Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study. *Diabetes Research and Clinical Practice*. 2016;120:15-23.
73. Kundu D, Roy A, Mandal T, Bandyopadhyay U, E Ghosh DR. Relation of microalbuminuria to glycosylated hemoglobin and duration of type 2 diabetes. *Nigerian Journal of Clinical Practice*. 2013;16(2).
74. Yadav R, Tiwari P, Dhanaraj E. Risk factors and complications of type 2 diabetes in Asians. *CRIPS*. 2008;9:8-12.
75. Friis K, Vind B, Simmons RK, Maindal HT. The Relationship between Health Literacy and Health Behaviour in People with Diabetes: A Danish Population-Based Study. *Journal of Diabetes Research*. 2016;2016.
76. ADA. Classification and diagnosis of diabetes. Sec. 2. in Standards of Medical Care in Diabetes-2017. *Diabetes Care*. 2017;40(1):S11-S24.

77. Chen H-M, Shen W-W, Ge Y-C, Zhang Y-D, Xie H-L, Liu Z-H. The relationship between obesity and diabetic nephropathy in China. *BMC Nephrology*. 2013;14(69).
78. Meguro S, Kabeya Y, Tanaka K, Kawai T, Tomita M, Katsuki T, et al. Past Obesity as well as Present Body Weight Status Is a Risk Factor for Diabetic Nephropathy. *International Journal of Endocrinology*. 2013;2013.
79. Maric-Bilkan C. Obesity and Diabetic Kidney Disease. *Med Chin North Am*. 2013;97:59-74.
80. Ali A, Taj A, Iqbal F, Amin MJ, Iqbal Z. Correlation between microalbuminuria and hypertension in Type 2 diabetic patients. *Pak J Med Sci*. 2014;30.
81. Parveen K, Siddiqui WA, Kausara MA, Kuddusa M, Shahida SMA, Arif JM. Diabetic Nephropathy- A Major Macrovascular Complication. *International Journal of Pharmaceutical Research & Allied Sciences*. 2016;5:132-58.
82. Takasaki K, Babazono T, Ishizawa K, Miura J, Uchigata Y. Relationship between diabetic nephropathy and depression: a cross-sectional analysis using the Diabetes Study from the Center of Tokyo Women's Medical University (DIACET). *BMJ Open Diabetes Research and Care*. 2016;4(e000310).
83. Fegan PG, Davis WA, Kamber N, Sivakumar S, Beilby J, Davis TME. Renin-angiotensin-aldosterone system blockade and urinary albumin excretion in community-based patients with Type 2 diabetes: The Fremantle Diabetes Study. *Diabetic Medicine*. 2011;28:849-55.
84. Tuttle KR. Protein kinase C- β inhibition for diabetic kidney disease. *Diabetes Research and Clinical Practice*. 2008;82s:s70-s4.
85. Ficociello LH, Rosolowsky ET, Niewczas MA, Maselli NJ, M.Weinberg J, Aschengrau A, et al. High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes. *Diabetes Care*. 2010;33:1337-43.
86. Adiga US, Malawadi B. Uric acid in Type 2 Diabetes mellitus with nephropathy. *International Journal of Clinical Biochemistry and Research*. 2016;3(3):340-2.
87. Lazarevic G, Antic S, Cvetkovic T, Vlahovic P, Tasic I, Stefanovic V. A physical activity programme and its effects on insulin resistance and oxidative defense in obese male patients with type 2 diabetes mellitus. *Diabetes Metab* 2006;32:583-90.
88. Ito D, Cao P, Kakihana T, Sato E, Suda C, Muroya Y, et al. Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats. *PLoS ONE*. 2015;9(e0138037).
89. Ahmed SB, Hovind P, Parving H-H, Rossing P, Price DA, Laffel LM, et al. Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy. *DIABETES CARE*. 2005;28.
90. Park H, Kim K. Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean Women. *BMC Women's Health*. 2013;13.

91. Gordis L. Chapter 10. Case-Conrol Studies and Other Study Design. Epidemiology 4th Ed. Philadelphia: Saunder Elsevier; 2009.
92. Lemeshow S, Jr DWH, Janelle Klar SKL. Adequacy of Sample Size in Heathh Studies: Wolrd Health Organization. John Wiley & Son. Ltd; 1990.
93. Dahlan MS. Statistik untuk Kedokteran dan Kesehatan. Jakarta: Salemba Medika; 2012.